Strides receives USFDA approval for its greenfield oral dosage facility in Singapore

Facility to provide growth capacities for regulated markets of US, Australia, UK and Europe and help expand manufacturing base

Bangalore, March 27, 2019 - Strides Pharma Science Limited (Strides) today announced that it has received USFDA approval for its greenfield oral dosage facility in Singapore.

Singapore oral dosage facility – For growth capacities

- With the commercialization of its manufacturing facility in Singapore, Strides will join the league of global pharmaceutical companies having a Manufacturing and Research and Development footprint in Singapore
- The facility will complement Strides' existing manufacturing base and will help meet increased demand from its fast-growing regulated markets business across US, Australia, UK and Europe
- Singapore is also amongst the list of designated countries under the Trade Agreements Act (TAA) making it eligible to supply goods under Federal Supply Schedule (FSS) contracts in the US. The manufacturing facility in Singapore will enable the Company to tap opportunities under various federal government procurement programs including procurements administered by Department of Veterans Affairs (VA).
- The facility operating at its peak capacity will produce ~1.4 billion tablets and hard gelatin capsules
- The facility has been built with emphasis on automation in production and quality control laboratories and has fully integrated manufacturing and packing lines
- The facility has already been approved by Health Science Authority (HSA) Singapore and Therapeutic Goods Administration (TGA) Australia
About Strides
Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India- Bangalore (two sites), Pondicherry and Chennai, Singapore, Italy- Milan, and Kenya- Nairobi. The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com

For further information, please contact:

<table>
<thead>
<tr>
<th>Strides</th>
<th>PR Consultancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Badree Komandur,</td>
<td>Fortuna PR</td>
</tr>
<tr>
<td>Executive Director - Finance</td>
<td>K Srinivas Reddy: +91 90005 27213</td>
</tr>
<tr>
<td>+91 80 6784 0747</td>
<td><a href="mailto:srinivas@fortunapr.com">srinivas@fortunapr.com</a></td>
</tr>
<tr>
<td></td>
<td>K Priya: +91 95354 25418</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:priya@fortunapr.com">priya@fortunapr.com</a></td>
</tr>
</tbody>
</table>

Investor Relations:
Kannan. N: +91 98450 54745
Vikesh Kumar: +91 80 6784 0827
Sandeep Baid : +91 80 6784 0791
Email: Sandeep.baid@strides.com

Strides Pharma Science Limited
(Formerly Strides Shasun Limited)
CIN : L24230MH1990PLC057062
Regd. Office: 201, ‘Devavrata’, Sector - 17, Vashi, Navi Mumbai - 400 703
Corp. Office: Strides House, Bannerghatta Road, Bangalore - 560076